June 27, 2023
Japan’s health ministry on June 26 approved a throng of new medicines and indications including Nihon Servier’s blood tumor agent Oncaspar (pegaspargase) and Taiho Pharmaceutical’s biliary tract cancer treatment Lytgobi (futibatinib). Oncaspar is an antitumor enzyme agent indicated for the...read more